IL-6 rescues the hyporesponsiveness of c-Rel deficient B cells independent of Bcl-xL, Mcl-1, and Bcl-2

被引:28
作者
Tumang, JR
Hsia, CY
Tian, WZ
Bromberg, JF
Liou, HC [1 ]
机构
[1] Cornell Univ, Weill Med Coll, Dept Med, Div Immunol, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
关键词
NF-kappa B/Rel; c-Rel knockout mice; cytokines; B lymphocytes;
D O I
10.1016/S0008-8749(02)00513-0
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The hematopoietically restricted member of the NF-kappaB/Rel family, c-Rel, is essential for B cell survival and proliferation. Here we demonstrate that the production of the interleukins 6, 10, and 15 (IL-6, IL-10, and IL-15) are diminished in c-Rel(-/-) B lymphocytes. In a manner similar to that seen in IL-6(-/-) B cells, resultant STAT activation is reduced in c-Rel(-/-) B cells following B cell receptor (BCR) ligation. Addition of either exogenous IL-6 or IL-10, but not IL-15, partially restores proliferation, and this occurs through enhanced cell survival rather than promoting cell cycle progression. This increase in viability occurs independently of Bcl-xL and Mcl-1 expression though, two survival genes reported to be downstream of IL-6 signaling. Nonetheless, transgenically expressed Bcl-xL, a direct c-Rel target gene in B cells, corrects not only the survival defect of c-Rel deficiency, but also partially ameliorates hypoproliferation. Together IL-6 and Bcl-xL are additive but incomplete in the restoration of proliferation. Known deficits in the induction of several key cell cycle components in c-Rel(-/-)B cells are not corrected upon treatment with exogenous cytokine. Together, these data demonstrate that IL-6 enhances B cell responses by employing multiple survival factors. (C) 2002 Elsevier Science (USA). All rights reserved.
引用
收藏
页码:47 / 57
页数:11
相关论文
共 50 条
[1]   Reversal of EBV immortalization precedes apoptosis in IL-6-induced human B cell terminal differentiation [J].
Altmeyer, A ;
Simmons, RC ;
Krajewski, S ;
Reed, JC ;
Bornkamm, GW ;
ChenKiang, S .
IMMUNITY, 1997, 7 (05) :667-677
[2]   Receptor engagement by viral interleukin-6 encoded by Kaposi sarcoma-associated herpesvirus [J].
Aoki, Y ;
Narazaki, M ;
Kishimoto, T ;
Tosato, G .
BLOOD, 2001, 98 (10) :3042-3049
[3]   The role of STATs in transcriptional control and their impact on cellular function [J].
Bromberg, J ;
Darnell, JE .
ONCOGENE, 2000, 19 (21) :2468-2473
[4]   Stat3 as an oncogene [J].
Bromberg, JF ;
Wrzeszczynska, MH ;
Devgan, G ;
Zhao, YX ;
Pestell, RG ;
Albanese, C ;
Darnell, JE .
CELL, 1999, 98 (03) :295-303
[5]  
BURDIN N, 1995, J IMMUNOL, V154, P2533
[6]   Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells [J].
Catlett-Falcone, R ;
Landowski, TH ;
Oshiro, MM ;
Turkson, J ;
Levitzki, A ;
Savino, R ;
Ciliberto, G ;
Moscinski, L ;
Fernández-Luna, JL ;
Nuñez, G ;
Dalton, WS ;
Jove, R .
IMMUNITY, 1999, 10 (01) :105-115
[7]  
Fan H, 2001, EUR J IMMUNOL, V31, P665, DOI 10.1002/1521-4141(200102)31:2<665::AID-IMMU665>3.0.CO
[8]  
2-1
[9]   Frequent aberrant immunoglobulin gene rearrangements in pro-B cells revealed by a bcl-x(L) transgene [J].
Fang, W ;
Mueller, DL ;
Pennell, CA ;
Rivard, JJ ;
Li, YS ;
Hardy, RR ;
Schlissel, MS ;
Behrens, TW .
IMMUNITY, 1996, 4 (03) :291-299
[10]  
Foussat A, 1999, EUR CYTOKINE NETW, V10, P501